MONDAY, Jan. 10, 2022 (HealthDay News) — Medicare has been told to reassess a significant premium increase it had announced that largely stemmed from the expensive new Alzheimer’s drug Aduhelm. U.S. Health and Human Services Secretary Xavier Becerra’s directive, which was announced on Monday, comes shortly after Aduhelm maker BiogenContinue Reading

MONDAY, Jan. 10, 2022 (HealthDay News) — More than 30 years after passage of the landmark Americans with Disabilities Act (ADA), many doctors still don’t know how to provide accessible care, a new study finds. “Despite the fact people with disabilities comprise 25% of the population, they often confront barriersContinue Reading

FRIDAY, Jan. 7, 2022 (HealthDay News) — A review of cases from 465 U.S. hospitals underscores the protection provided by COVID-19 vaccines. The new review — by researchers at the U.S. National Institutes of Health — found that vaccinated adults who got breakthrough infections rarely got severely ill. Respiratory failure,Continue Reading

FRIDAY, Jan. 7, 2022 (HealthDay News) — Following a months-long and unprecedented review, Medicare officials expect to announce within the next couple of weeks whether the program will cover the controversial Alzheimer’s drug Aduhelm. The drug’s benefits are in question and its annual price tag tops $28,000. The U.S. CentersContinue Reading